Mithra Pharmaceuticals S.A.
MITPF · OTC
12/31/2023 | 6/30/2023 | 12/31/2022 | 6/30/2022 | |
|---|---|---|---|---|
| Revenue | $33 | $7 | $56 | $11 |
| % Growth | 370.8% | -87.4% | 389.9% | – |
| Cost of Goods Sold | $20 | $15 | $19 | $13 |
| Gross Profit | $14 | -$8 | $37 | -$2 |
| % Margin | 40.9% | -107.3% | 66.5% | -13.7% |
| R&D Expenses | $31 | $32 | $37 | $28 |
| G&A Expenses | $15 | $7 | $8 | $7 |
| SG&A Expenses | $10 | $2 | $2 | $2 |
| Sales & Mktg Exp. | $1 | $1 | $1 | $1 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $41 | $35 | $39 | $30 |
| Operating Income | -$28 | -$42 | -$2 | -$31 |
| % Margin | -83.5% | -599.5% | -3.5% | -277.1% |
| Other Income/Exp. Net | -$83 | -$10 | $18 | $2 |
| Pre-Tax Income | -$110 | -$52 | $16 | -$30 |
| Tax Expense | $13 | -$1 | $45 | $1 |
| Net Income | -$123 | -$50 | -$28 | -$31 |
| % Margin | -371.5% | -717.4% | -51% | -275.1% |
| EPS | -1.78 | -0.88 | -0.52 | -0.69 |
| % Growth | -102.3% | -69.2% | 24.6% | – |
| EPS Diluted | -1.78 | -0.88 | -0.52 | -0.69 |
| Weighted Avg Shares Out | 69 | 57 | 54 | 45 |
| Weighted Avg Shares Out Dil | 69 | 57 | 54 | 45 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1 | $1 | $6 | $0 |
| Interest Expense | $12 | $11 | $16 | $8 |
| Depreciation & Amortization | $6 | $6 | $6 | $6 |
| EBITDA | -$19 | -$34 | $7 | -$22 |
| % Margin | -56.5% | -484.2% | 13.3% | -191.2% |